Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | Phase 1 | withdrawn | Dec 2, 2008 | M.D. Anderson Cancer Center | Sponsor terminated. | Other (stated, no rule matched) |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | Phase 3 | terminated | Aug 9, 2005 | Emergent Product Development Seattle LLC | New sponsor, other treatments available | Other (stated, no rule matched) |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00151736 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of… | Phase 2 | terminated | Sep 9, 2005 | Cephalon | not stated | Not stated |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or… | Phase 2 | withdrawn | Sep 25, 2008 | University of Kentucky | Funding was withdrawn due to insufficient accrual | Enrollment / accrual |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | Phase 2 | withdrawn | Jul 20, 2007 | CABYC | IMP new owner decision | Other (stated, no rule matched) |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | Phase 2 | terminated | May 21, 2010 | The Christie NHS Foundation Trust | Potential safety issue of second primary malignancies in patients treated with lenalidomide. | Safety / toxicity |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | Phase 1 | terminated | Feb 1, 2007 | Callisto Pharmaceuticals | Participants are no longer being examined or treated. | Other (stated, no rule matched) |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | Phase 2 | terminated | Sep 3, 2007 | CancerCare Manitoba | Terminated due to poor accrual. | Enrollment / accrual |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic… | Phase 2 | terminated | May 18, 2010 | Nevada Cancer Institute | Low enrollment | Enrollment / accrual |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a… | Phase 2 | withdrawn | May 26, 2010 | Nevada Cancer Institute | PI left institution | Investigator |
| NCT00187005 | Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Phase 3 | terminated | Sep 16, 2005 | St. Jude Children's Research Hospital | Toxicity | Safety / toxicity |
| NCT00646165 | Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia | Phase 1 | terminated | Mar 28, 2008 | Mundipharma Research Limited | Poor recruitment and change in development strategy | Enrollment / accrual |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | Phase 1 | terminated | Apr 27, 2006 | Biogen | Discontinuation of program | Other (stated, no rule matched) |
| NCT00918450 | Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic… | Phase 2 | withdrawn | Jun 11, 2009 | Abbott | Sponsor has decided to not proceed with this study. | Other (stated, no rule matched) |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | Phase 3 | terminated | Mar 23, 2006 | Radboud University Medical Center | Interim analysis has shown that the objectives of this study can not be reached | Efficacy / futility |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | Phase 1 | terminated | Jun 27, 2006 | Biogen | Sponsor's decision | Sponsor / business decision |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell… | Phase 2 | withdrawn | Jun 13, 2007 | Cylene Pharmaceuticals | This study was withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous… | Phase 1 / Phase 2 | withdrawn | May 13, 2008 | MedImmune LLC | Replacing this trial with a new trial. | Other (stated, no rule matched) |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | Phase 1 | terminated | Oct 7, 2005 | Exelixis | Study closed due to slow enrollment | Enrollment / accrual |
| NCT00302861 | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Mar 15, 2006 | Genitope Corporation | not stated | Not stated |
| NCT00517218 | This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the… | Phase 3 | withdrawn | Aug 16, 2007 | Genta Incorporated | not stated | Not stated |
| NCT00165087 | Treatment of Childhood Acute Lymphoblastic Leukemia | Phase 3 | terminated | Sep 14, 2005 | Dana-Farber Cancer Institute | Terminated by IRB for continuing review | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 1, 2012source: clinicaltrials